Grants for Special district governments - Health

This funding opportunity provides financial support for early-stage researchers in the U.S. to explore innovative studies on HIV-related health issues, such as comorbidities and coinfections, with the potential to transform understanding and treatment in this field.

The purpose of this initiative is to advance research that reduces firearm injury and disparities through the development and evaluation of firearm injury primary prevention interventions leveraging community healthcare settings. This funding opportunity solicits applications that focus on primary prevention of firearm injury leveraging community healthcare settings. Applications may propose intervention studies with a rigorous design including, but not limited to, policy implementation studies, natural experiments and other studies with a quasi-experimental design, as well as those meeting the NIH definition of a clinical trial. Aims may focus on efficacy, effectiveness, or hybrid effectiveness/implementation research. Health or behavioral outcomes for this funding opportunity should be appropriate to the aims and should include, but are not limited to, changes in behavior related to firearm injury prevention and firearm safety procedures, and implementation outcomes. Change in knowledge of firearm injury prevention measures may be a secondary outcome (e.g., as a mechanism of action) but should not be the focus of the project. Multi-level, multi-disciplinary interventions and outcomes are encouraged, including individual, interpersonal, organizational, and community levels. Individual level outcomes should be one of the outcome levels included. Rigorous methods that address potential sources of bias that are appropriate to the study design are expected. Intervention studies are expected to include a theory-informed examination of the mechanisms of intervention effects. Projects that are responsive to this funding opportunity include R01 studies of all size, from small, single-site, three-year projects such as to adapt an intervention to the community or to test efficacy of an intervention, to large multi-site trials to test effectiveness and implementation strategies. Applications that meet any of the non-responsiveness criteria will be considered non-responsive and will not be reviewed. Implementation studies should include an evaluation of the effectiveness of the intervention in the site or sites. Years requested and project budgets should reflect the scope of the project. A description of plans for community engagement, including clear justification of the planned approach, is required. Projects that focus on populations that experience health disparities are highly encouraged.

The "CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development" grant aims to fund the early-stage development of treatments to reduce the harmful health effects caused by exposure to toxic chemicals, which could be used in terrorist attacks or accidentally released from industrial sites, with the end goal of producing at least one well-characterized therapeutic candidate.

This funding opportunity is designed to support research centers in developing innovative vaccines against hepatitis C virus, targeting a wide range of applicants including universities, nonprofits, and government entities.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes.Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes. Background Obesity: Obesity will soon surpass smoking tobacco as the number one cause of preventable death both in the United States and worldwide. Bariatric (metabolic) surgery is the most effective strategy to achieve significant initial and sustained weight loss among individuals who are morbidly obese. Bariatric surgery provides dramatic improvement in metabolic function, associated with a reduction in type 2 diabetes mellitus (T2DM) and cardiovascular (CV) risk. Bariatric surgery also appears to reduce the risk of certain obesity-related cancers, although which cancers are favorably impacted vary by study, and the mechanism(s) driving this risk reduction is mostly speculative. Bariatric surgery is performed in over 250,000 people in the U.S. annually, and the frequency is rising. Studies evaluating which bariatric surgery procedure(s) are most effective in cancer risk reduction could help bring to light new pathways to target for cancer prevention. Bariatric Surgery: Importantly, it is not yet clear from clinical and preclinical studies if the benefit from bariatric surgery arises from weight loss alone or if there is also a surgery-specific benefit. One mechanism for a possible surgery-specific effect is elevated bile acids (BA), both intestinal and circulating, after gastric bypass surgery such as Roux-en-Y gastric bypass (RYGB) that are proposed to be central to weight loss and other metabolic benefits. The interaction between BA and intestinal microbes is also an area of intense interest. Studies have identified important changes after bariatric surgery in the composition and function of the gut microbiome, which may mediate bariatric surgery effects. Fecal microbiota transplantation (FMT) from humans or mice that had undergone bariatric surgery to germ-free recipient mice showed decreased weight gain and decreased adiposity are both transmissible traits. In addition, FMT induced important host metabolic changes including decreased energy harvest from the diet, increased resting energy expenditure, and increased lipid utilization. The data suggest a causal link between gut microbiota and the metabolic and weight loss effects of bariatric surgery. If validated, the findings will provide insight into the mechanisms driving the benefit of bariatric surgery on cancer risk and would be useful to further scientific understanding and patient care. Animal Models: Several diets or genetically induced animal models of obesity have consistently demonstrated the benefits of weight loss on cancer risk, and these obesity-induced tumor models may be adaptable to bariatric surgery studies, such as the Kras model of pancreatic cancer. Animal models have been developed to study the effects of bariatric surgery. Rodent animal models are most often used due to feasibility (low cost, ease of housing) and have been used extensively to study the mechanism(s) of bariatric surgery responsible for the reduction or elimination of T2DM and CV risk. However, very little has been reported on bariatric surgery and cancer risk despite the fact that both rat and murine models of mammary and other cancers develop in 6 months or less, making it feasible to assess mechanistic changes that influence cancer risk. Bariatric Surgery and Cancer Risk: Obese patients undergo bariatric surgery for a variety of reasons, including weight loss and improvement in metabolic dysfunction. Physician advice regarding the potential benefit of bariatric surgery and cancer risk reduction can currently only be given in generalities based on large-scale studies and not targeted to the individual. Many but not all bariatric surgery investigations document an overall cancer risk reduction among women but not men. Some but not all bariatric surgery studies have found that both women and men undergoing bariatric surgery have an increased risk of colorectal cancer (CRC). Older studies which assessed bariatric surgery and cancer risk may not be useful to guide targeted advice to patients, as one of the most common procedures performed in the past, gastric banding, is only performed in 1% of bariatric surgery procedures today. The two most common bariatric surgery procedures currently performed are sleeve gastrectomy and RYGB. As such, planned animal and/or human studies should focus on the mechanistic effects of the two procedures that are currently in common use. Human biospecimens and/or data may be available from cohorts to enhance the studies proposed including the Longitudinal Assessment of Bariatric Surgery (LABS), Adolescent Bariatrics: Assessing Health Benefits & Risks (Teen-LABS), and NCI Cohort Consortium Members. Applications that include collaborators from fields outside of cancer research will be given special programmatic consideration. Responsive applications may investigate animal models, human studies, or a combination of both. General Area of Research and Scope of Work for this FOA General Area of Research Examples of relevant areas of research include but are not limited to: Do alterations in cancer risk biomarkers occur before weight loss? If so, in what organ, tissue, or cell type do they originate? Is maximum weight loss or long-term weight loss more important for cancer risk reduction? If so, how do the two differ at a cellular and/or biochemical level? What mechanism(s) explain the evidence that bariatric surgery is more beneficial in cancer risk reduction in women than men? Does bariatric surgery increase or decrease the risk of CRC, and if so, what are the mechanism(s)? Which cancers are decreased in incidence by bariatric surgery, and what are the mechanism(s) that explain the effect? Are any cancers increased in incidence by bariatric surgery? If so, through what mechanism(s)? Does the specific bariatric surgery procedure have an impact on cancer risk? If so, what are the mechanism(s) driving the difference in impact? Does racial or ethnic background influence the impact of bariatric surgery on cancer risk, and if so, what are the mechanism(s) involved? How does bariatric surgery affect the penetrance of high-risk genetic predisposition to cancer? Scope of Work and Additional Guidance It is anticipated that studies will evaluate bariatric surgery animal models where a significant proportion of the animals develop cancer. Similarly, human studies involving individuals who will or have undergone bariatric surgery are also encouraged, so long as within the cohort to be studied the number of enrolled subjects who develop cancer is adequate to for a statistically powered endpoint linking cancer (and not a biomarker of cancer) to a molecular mechanism as the driver of cancer. When appropriate and feasible, the investigators may want to evaluate mechanisms influenced by bariatric surgery in animal models of cancer and evaluate potential changes that might correlate with humans due to bariatric surgery. We define mechanism as a biologic endpoint based on analyzed samples from bariatric surgery animal models or from subjects who have or are planned to undergo bariatric surgery. This FOA does not support studies where an epidemiologic endpoint is the primary aim of the project. The mechanism(s) to be studied should evaluate samples collected from animals or humans who have undergone bariatric surgery who did or did not develop cancer. If both animals and humans are studied, the mechanisms chosen should be based on a cancer endpoint. Applications Not Responsive to This FOA The following types of activities remain outside the scope of this FOA, and applications proposing them are non-responsive to this FOA and will not be reviewed. This FOA is not intended for epidemiologic studies, where the primary endpoint is the assessment of cancer in a cohort of animals or humans, which has undergone bariatric surgery and mechanistic studies evaluating bodily fluid or tissue samples are nonexistent or of secondary endpoints. Application that focuses entirely on in vitro investigations. Epidemiologic investigations as the primary focus of the application. Animal or human studies that do not evaluate tissue and/or bodily fluid samples collected from participants who have undergone bariatric surgery, some of which developed cancer after surgery. Application, which includes a clinical trial that does not have a bariatric surgeon as a key investigator on the team. NOTE: Applicants to this FOA are strongly encouraged to contact NCI staff as soon as possible in the development of the application (preferably no later than 12 weeks prior to the application due date) to discuss the details of their proposed clinical trial, so that NCI staff can help the applicant understand whether the proposed clinical trial is within the goals and mission of the NCI and is appropriate for this FOA.

This funding opportunity provides financial support for research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underrepresented communities, by addressing barriers and promoting equitable health outcomes.

This grant provides funding to health organizations in Cameroon to strengthen their ability to prevent, detect, and respond to public health threats and improve overall health security.

This funding opportunity supports research institutions and organizations conducting experimental studies with human participants to explore new brain stimulation techniques for treating substance use disorders.

This funding opportunity provides financial support for predoctoral and postdoctoral researchers in New York State to conduct innovative research aimed at developing treatments or cures for spinal cord injuries.

This funding opportunity is designed to help schools collect and utilize data to improve the health and well-being of adolescents by tracking their behaviors and experiences over time.

The Indiana Department of Health (IDOH) is offering a grant opportunity to provide intranasal naloxone kits to first responders in rural counties of Indiana. The grant, funded in part by the Substance Abuse Mental Health Services Administration (SAMHSA) under the First Responder Comprehensive Addiction and Recovery Act, aims to enhance the capacity of first responders to address opioid-related incidents. Eligible first responders include professional and volunteer firefighters, law enforcement officers, paramedics, emergency medical technicians, and other recognized volunteer organizations. Grant recipients are required to administer naloxone as needed, report usage via an online survey, and refrain from selling or distributing the naloxone doses. The grant period runs from October 2023 through September 2024, with a total funding amount of $287,500 available. Non financial aid, only Naloxone kits

This funding opportunity supports researchers and organizations in developing advanced tissue-engineered technologies that mimic cancer biology to improve cancer detection, treatment, and prevention.

This funding opportunity is designed to strengthen clinical and translational research capabilities in health organizations located in underserved states, enabling them to address local healthcare challenges through enhanced infrastructure, workforce development, and community engagement.

This funding opportunity provides financial support for organizations to develop and validate digital therapeutic technologies designed to treat substance use disorders, with the goal of achieving FDA authorization.

This grant provides funding for clinical trials investigating the safety and effectiveness of amyloid-beta antibody therapies in patients with mild cognitive impairment or dementia who also show signs of Lewy Body Dementia, with a focus on diverse and underrepresented populations.

This funding opportunity supports postdoctoral researchers transitioning to independent faculty positions in U.S. academic institutions, specifically those planning to lead their own clinical trials or related studies in mental health research.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate translational efforts in developing and implementing accessibility devices or interventions that apply new technologies to address challenges faced by individuals living with visual impairment. Critical elements of applications include a clear set of milestones that support development and testing of the tool, device, or intervention proposed; multidisciplinary and collaborative teams that include individuals with lived experience; and a tractable dissemination plan. The overall goal of the program is to push the boundaries of innovation in technology development to address accessibility needs of individuals with visual impairment and create resources that will be made available to the community. This NOFO uses a milestone driven and phased mechanism of award. Initial technology development and feasibility activities (R61 phase) may transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. All applications must address both R61 and R33 phases.

This funding opportunity supports innovative research teams in developing and implementing advanced artificial intelligence models to improve HIV diagnosis, prevention, and treatment, while ensuring ethical practices and community engagement.

This Notice of Funding Opportunity (NOFO) invites new applications for Centers for Collaborative Research in Fragile X andFMR1-Associated Conditions (hereafter termed "Fragile X Centers"). Despite many remarkable advances in fundamental knowledge about FMR1-associated conditions, gaps in knowledge remain about the processes that drive the variability in clinical features (phenotypic heterogeneity) among affected individuals. In this round of competition, therefore, all centers will be required to identify an overarching theme directed at broadening our understanding of factors underlying the phenotypic heterogeneity and/or variability in response to interventions seen in one or more FMR1 associated conditions. Successful Fragile X Centers will be composed of multidisciplinary teams of basic, translational, clinical, and/or data science investigators applying precision medicine approaches (seeking to understand which mechanisms and interventions are most applicable to specific individuals or groups) to address the center's proposed overarching theme. This NOFO includes specific requirements about inclusion of research on human subjects or human phenotypic data; diversity of participants or materials being studied; the types of allowable clinical trials; and involvement of early-stage investigators. Applications that do not adhere to these requirements will be considered nonresponsive to this NOFO and will be withdrawn. In addition, this NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.Applicants are strongly encouraged to read the NOFO instructions carefully and view the availablePEDP guidance material.